A Zietman

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi The case for neoadjuvant androgen suppression before radiation therapy
    A L Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Mol Urol 4:203-8;discussion 215. 2000
  2. ncbi Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial
    Anthony L Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    JAMA 294:1233-9. 2005
  3. ncbi PSA bounces after neoadjuvant androgen deprivation and external beam radiation: impact on definitions of failure
    Anthony L Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 62:714-8. 2005
  4. ncbi Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors
    Anthony L Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Cox 302, Boston, MA 02114, USA
    J Urol 170:1772-6. 2003
  5. ncbi Active surveillance: a safe, low-cost prognostic test for prostate cancer
    Anthony Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    BJU Int 101:1059-60. 2008
  6. ncbi A clinical approach to technology assessment: how do we and how should we choose the right treatment?
    Anthony Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Semin Radiat Oncol 22:11-7. 2012
  7. ncbi The future of radiation oncology: the evolution, diversification, and survival of the specialty
    Anthony Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Semin Radiat Oncol 18:207-13. 2008
  8. ncbi Localized prostate cancer: brachytherapy
    Anthony L Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston 02114, USA
    Curr Treat Options Oncol 3:429-36. 2002
  9. ncbi Neoadjuvant androgen suppression and external beam radiation therapy
    Anthony L Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, USA
    Front Radiat Ther Oncol 36:87-98. 2002
  10. ncbi The Patterns of Care Survey of radiation therapy in localized prostate cancer: similarities between the practice nationally and in minority-rich areas
    A Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 50:75-80. 2001

Detail Information

Publications60

  1. ncbi The case for neoadjuvant androgen suppression before radiation therapy
    A L Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Mol Urol 4:203-8;discussion 215. 2000
    ..It cannot be assumed that the same advantage will hold with brachytherapy...
  2. ncbi Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial
    Anthony L Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    JAMA 294:1233-9. 2005
    ..Clinically localized prostate cancer is very prevalent among US men, but recurrence after treatment with conventional radiation therapy is common...
  3. ncbi PSA bounces after neoadjuvant androgen deprivation and external beam radiation: impact on definitions of failure
    Anthony L Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 62:714-8. 2005
    ..To determine the characteristics of prostate specific antigen (PSA) bounces after external beam radiation therapy (EBRT) with neoadjuvant androgen deprivation and their impact on definitions of biochemical failure...
  4. ncbi Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors
    Anthony L Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Cox 302, Boston, MA 02114, USA
    J Urol 170:1772-6. 2003
    ..Concern exists about the function of the retained bladder after such therapy...
  5. ncbi Active surveillance: a safe, low-cost prognostic test for prostate cancer
    Anthony Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    BJU Int 101:1059-60. 2008
  6. ncbi A clinical approach to technology assessment: how do we and how should we choose the right treatment?
    Anthony Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Semin Radiat Oncol 22:11-7. 2012
    ..We also discuss the role that independent bodies may have in determining whether or not a new device is not only safe but also adds to the medical landscape in a way that justifies its cost...
  7. ncbi The future of radiation oncology: the evolution, diversification, and survival of the specialty
    Anthony Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Semin Radiat Oncol 18:207-13. 2008
    ..This article discusses these threats to the field and examines strategies by which we may evolve, diversify, and thrive...
  8. ncbi Localized prostate cancer: brachytherapy
    Anthony L Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston 02114, USA
    Curr Treat Options Oncol 3:429-36. 2002
    ..Their use remains investigational. Therefore, prostate brachytherapy remains a reasonable option for men with early stage disease, but there remain unanswered questions regarding long-term efficacy and morbidity...
  9. ncbi Neoadjuvant androgen suppression and external beam radiation therapy
    Anthony L Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, USA
    Front Radiat Ther Oncol 36:87-98. 2002
  10. ncbi The Patterns of Care Survey of radiation therapy in localized prostate cancer: similarities between the practice nationally and in minority-rich areas
    A Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 50:75-80. 2001
    ..This study was designed to determine whether the stage of presentation and the quality of radiation treatment delivered are comparable between Caucasian and minority patients nationally and within minority-rich areas...
  11. ncbi Freedom from castration: an alternative end point for men with localized prostate cancer treated by external beam radiation therapy
    Anthony Zietman
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 53:1152-9. 2002
    ..This study was designed to determine what proportion of men require subsequent ADT if their localized prostate cancer is first treated by radiation...
  12. ncbi Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09
    Anthony L Zietman
    Department of Radiation Oncology, Cox 3, Massachusetts General Hospital, Boston MA 02114, USA
    J Clin Oncol 28:1106-11. 2010
    ..This was achieved without an increase in grade >/= 3 late urinary or rectal morbidity...
  13. ncbi Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-2004. A 63-year-old man with metastatic prostate carcinoma refractory to hormone therapy
    Donald S Kaufman
    Division of Medical Oncology, Department of Medicine, Massachusetts General Hospital, USA
    N Engl J Med 351:171-8. 2004
  14. ncbi Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era
    Deborah A Kuban
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 57:915-28. 2003
    ..To report the long-term outcome for patients with Stage T1-T2 adenocarcinoma of the prostate definitively irradiated in the prostate-specific antigen (PSA) era...
  15. ncbi Radiation, chemotherapy and transurethral surgery: an organ-sparing alternative to the radical cystectomy
    Anthony L Zietman
    Massachusetts General Hospital, Harvard Medical School, Boston, Mass, USA
    Front Radiat Ther Oncol 36:131-46. 2002
  16. ncbi Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 59:1053-61. 2004
    ..To report changing trends in external beam radiotherapy (EBRT) delivery practice for clinically localized prostate cancer as determined from the 1999 survey from the American College of Radiology National Patterns of Care Study...
  17. ncbi Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure
    Michael E Ray
    Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0010, USA
    Urology 68:1257-62. 2006
    ..To determine whether nadir prostate-specific antigen (PSA) levels within 12 months (nadir PSA12) after completion of radiotherapy (RT) can be used as an early marker of recurrence risk...
  18. ncbi The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Jennifer Y Wo
    Harvard Radiation Oncology Programm, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    BJU Int 104:179-83. 2009
    ....
  19. ncbi RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy
    Michael P Hagan
    Medical College of Virginia Hospitals, Richmond, VA 23298 0058, USA
    Int J Radiat Oncol Biol Phys 57:665-72. 2003
    ..With only 45% of patients completing three cycles of MCV, this form of adjuvant chemotherapy appears to be poorly tolerated by most patients...
  20. ncbi Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer
    Jeff M Michalski
    Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Int J Radiat Oncol Biol Phys 76:361-8. 2010
    ..To define a prostate fossa clinical target volume (PF-CTV) for Radiation Therapy Oncology Group (RTOG) trials using postoperative radiotherapy for prostate cancer...
  21. ncbi Management of complications of prostate cancer treatment
    M Dror Michaelson
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
    CA Cancer J Clin 58:196-213. 2008
    ..Ongoing and planned clinical trials will continue to address strategies to prevent treatment-related side effects and improve quality of life for men with prostate cancer...
  22. ncbi Case records of the Massachusetts General Hospital. Case 18-2007. A 54-year-old man with early-stage prostate cancer
    Donald S Kaufman
    Department of Hematology-Oncology, Massachusetts General Hospital, USA
    N Engl J Med 356:2515-20. 2007
  23. ncbi High-dose external beam radiation for localized prostate cancer: current status and future challenges
    Paul L Nguyen
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Cancer J 13:295-301. 2007
    ....
  24. ncbi Bladder preservation: optimizing radiotherapy and integrated treatment strategies
    Raymond H Mak
    Department of Radiation, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    BJU Int 102:1345-53. 2008
    ..Future work will continue to refine the bladder-preserving approach to improve survival and local control...
  25. ncbi Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy
    Robert W Ross
    Center for Molecular Imaging Research, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Imaging 33:301-5. 2009
    ..Six (23%) of the 26 patients, previously believed to be node negative, tested lymph node positive by LNMRI. A total of nine positive lymph nodes were identified in these six patients, none of which were enlarged based on size criteria...
  26. ncbi Comparison of biochemical failure definitions for permanent prostate brachytherapy
    Deborah A Kuban
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 65:1487-93. 2006
    ..To assess prostate-specific antigen (PSA) failure definitions for patients with Stage T1-T2 prostate cancer treated by permanent prostate brachytherapy...
  27. ncbi PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis
    Michael E Ray
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
    Int J Radiat Oncol Biol Phys 64:1140-50. 2006
    ....
  28. ncbi Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors
    Ashish K Chawla
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Urology 59:726-31. 2002
    ..Those with favorable biochemical and pathologic tumor features are most likely to remain disease free...
  29. ncbi Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences
    William U Shipley
    Department of Radiation Oncology, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02138, USA
    Semin Radiat Oncol 15:36-41. 2005
    ..This preserves the urinary diversion options open to the surgeon as well as brings forward the time to a salvage procedure should it be needed...
  30. ncbi Dose escalation in localized prostate cancer: make no assumptions
    Anthony L Zietman
    Int J Radiat Oncol Biol Phys 54:635-6. 2002
  31. ncbi Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy
    Helen A Shih
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 63:1262-9. 2005
    ..quot; We employed a novel magnetic resonance lymphangiographic technique to highlight the likely sites of occult nodal metastasis from prostate cancer...
  32. ncbi Changes in body composition during androgen deprivation therapy for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 87:599-603. 2002
    ..Increased fatness resulted primarily from accumulation of sc rather than intraabdominal adipose tissue...
  33. ncbi Influence of follow-up bias on PSA failure after external beam radiotherapy for localized prostate cancer: results from a 10-year cohort analysis
    John J Coen
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 57:621-8. 2003
    ..To estimate the biases inherent in prostate cancer outcome that arise from different failure end points and variations in follow-up time and intensity using a cohort of men with long follow-up...
  34. ncbi Why does androgen deprivation enhance the results of radiation therapy?
    Jennifer Y Wo
    Harvard Radiation Oncology Program, Boston, MA 02114, USA
    Urol Oncol 26:522-9. 2008
    ..There are ongoing clinical trials that will hopefully better define patient populations that will benefit from hormonal deprivation therapy...
  35. ncbi Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy
    Donald S Kaufman
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Urology 73:833-7. 2009
    ..To evaluate the safety, tolerance, protocol completion rate, tumor response rate, and patient survival of chemoradiotherapy for patients with muscle-invasive operable bladder cancer...
  36. ncbi Bladder-sparing approaches to invasive disease
    Jason A Efstathiou
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Cox 3, Boston, MA 02114, USA
    World J Urol 24:517-29. 2006
    ..Future work will continue to optimize the bladder-sparing regimen while limiting toxicity...
  37. ncbi Proton radiation for localized prostate cancer
    John J Coen
    Massachusetts General Hospital, Department of Radiation Oncology, Harvard Medical School, 100 Blossom Street, Boston, MA 02114 2617, USA
    Nat Rev Urol 6:324-30. 2009
    ..This technique would be particularly well suited to partial prostate 'boosts', hypofractionation regimens and stereotactic delivery of radiation, all new approaches to prostate cancer that are being investigated...
  38. ncbi Life, liberty, and the pursuit of protons: an evidence-based review of the role of particle therapy in the treatment of prostate cancer
    Jason A Efstathiou
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Cancer J 15:312-8. 2009
    ....
  39. ncbi Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial
    Paul L Nguyen
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 78:1081-5. 2010
    ..2 GyE) or high-dose (79.2 GyE) radiation for prostate cancer...
  40. ncbi Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer
    James A Talcott
    Center for Outcomes Research, MGH Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA
    JAMA 303:1046-53. 2010
    ..Increased radiation doses improve prostate cancer control but also increase toxicity to adjacent normal tissue. Proton radiation may attenuate adverse effects...
  41. ncbi Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases
    John J Coen
    Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 3, Boston, MA 02114, USA
    J Clin Oncol 20:3199-205. 2002
    ..To assess whether failure to maintain local control (LC) of prostate cancer after radiation therapy results in a higher incidence of distant metastasis (DM)...
  42. ncbi Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison
    Alexei Trofimov
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 69:444-53. 2007
    ..To compare intensity-modulated photon radiotherapy (IMRT) with three-dimensional conformal proton therapy (3D-CPT) for early-stage prostate cancer, and explore the potential utility of intensity-modulated proton therapy (IMPT)...
  43. ncbi Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer
    Jason A Efstathiou
    Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 71:1302-8. 2008
    ..We investigated whether BMI is associated with PSA failure in men treated with brachytherapy for clinically localized prostate cancer...
  44. ncbi External beam radiation treatment for rectal cancer is associated with a decrease in subsequent prostate cancer diagnosis
    Karen E Hoffman
    Harvard Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 112:943-9. 2008
    ..The effect of this incidental exposure on subsequent prostate cancer diagnosis was investigated using the Surveillance, Epidemiology, and End Results (SEER) cancer registry...
  45. ncbi Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 67:327-33. 2007
    ..To assess long-term prostate-specific antigen (PSA) outcome after permanent prostate brachytherapy (BT) and identify predictors of improved disease-free survival...
  46. ncbi Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer
    Henry K Tsai
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Urology 68:1188-92. 2006
    ..To assess whether statin use improves local control (LC) in patients undergoing organ-preserving trimodality therapy for muscle-invasive bladder cancer...
  47. ncbi Prostatectomy or watchful waiting in prostate cancer
    John J Coen
    N Engl J Med 348:170-1; author reply 170-1. 2003
  48. ncbi Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis
    Eric M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 107:1496-502. 2006
    ....
  49. ncbi Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome
    Matthew R Smith
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 112:2188-94. 2008
    ..To the authors' knowledge, however, less is known regarding the effects of GnRH agonists on other attributes of the metabolic syndrome...
  50. ncbi Proton-beam vs intensity-modulated radiation therapy. Which is best for treating prostate cancer?
    Paul L Nguyen
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, MA 02114, USA
    Oncology (Williston Park) 22:748-54; discussion 754, 757. 2008
    ..In this article, we review the current status of the evidence supporting the use of protons in prostate cancer and discuss the active controversies that surround this modality...
  51. ncbi The Titanic and the Iceberg: prostate proton therapy and health care economics
    Anthony L Zietman
    J Clin Oncol 25:3565-6. 2007
  52. ncbi Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups
    Howard D Thames
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, and Department of Radiation Oncology, William Beaumont Hospital, Deroit, MI, USA
    Int J Radiat Oncol Biol Phys 65:975-81. 2006
    ....
  53. ncbi Correction: Inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate
    Anthony L Zietman
    JAMA 299:898-9. 2008
  54. ncbi Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis
    Eric M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    J Urol 173:797-802. 2005
    ..In this report we determined the sensitivity and specificity of several BF definitions using distant failure (DF) alone or clinical failure (CF), defined as local failure (LF) and/or DF...
  55. ncbi Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition
    Matthew R Smith
    Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 22:2546-53. 2004
    ..Less is known about the effects of bicalutamide monotherapy on bone mineral density and body composition...
  56. ncbi Newer imaging modalities to assist with target localization in the radiation treatment of prostate cancer and possible lymph node metastases
    Subhash S John
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 71:S43-7. 2008
    ..The concepts of biologic target volume, real target volume, and multidimensional conformal radiotherapy are being explored...
  57. ncbi Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancer
    John J Coen
    Department of Radiation Oncology, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA
    Urol Oncol 25:76-84. 2007
    ..Radiation is a very effective palliative agent for patients with locally advanced or metastatic disease. It can palliate bleeding and pain for patients with local progression or alleviate pain from bony metastases...
  58. ncbi Long-term durability of PSA failure-free survival after radiotherapy for localized prostate cancer
    Torunn I Yock
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 54:420-6. 2002
    ..The hazard rates of biochemical progression in the 6-10 years after treatment are low and are comparable to those published for prostatectomy series...
  59. ncbi Case records of the Massachusetts General Medicine. Weekly clinicopathological exercises. Case 9-2003. An 18-year-old man with back and leg pain and a nondiagnostic biopsy specimen
    Alison M Friedmann
    Department of Pediatric Hematology/Oncology, Massachusetts General Hospital, Boston, USA
    N Engl J Med 348:1150-8. 2003
  60. ncbi Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo
    Min Zhang
    Department of Radiation Oncology, Massachusetts General Hospital/Harvard Medical School Boston, Massachusetts 02114, USA
    Prostate 64:293-302. 2005
    ..CONCLUSIONS: Survivin mediates paclitaxel-resistance in prostate cancer cells. The inhibition of Survivin sensitizes prostate cancer cells to paclitaxel-induced apoptosis through a caspase-dependant mechanism in vitro and in vivo...